Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Gout Flares (β-RELIEVED)
NCT01029652Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Oct 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of canakinumab in gout, sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT01029652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029652.